The Food and Drug Administration (FDA) has requested that manufacturers of some Glucagon‐Like Peptide‐1 Receptor Agonists (GLP‐1 R A) remove warnings about suicidal behavior and ideation from labels. The request in a January 13, 2026 letter is an “update” on the FDA's ongoing evaluation of this issue. In the January letter, the FDA stated that it “did not identify an increased risk of suicidal ideation or behavior with the use of GLP‐1 RA medications.” Below is the public information from the letter.
A Mon, study studied this question.